Page 78 - 2019_03-Haematologica-web

M.D. Cappellini et al. Federation; 2014.
10. Rund D. Thalassemia 2016: modern medi- cine battles an ancient disease. Am J Hematol. 2016;91(1):15-21.
11. Haghpanah S, Nasirabadi S, Ghaffarpasand F, et al. Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Med J. 2013;131(3):166-172.
12. Dahlui M, Hishamshah MI, Rahman AJ, Aljunid SM. Quality of life in transfusion- dependent thalassemia patients on desfer- rioxamine treatment. Singapore Med J. 2009;50(8):794-799.
13. Baronciani D, Angelucci E, Potschger U, et al. Hematopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Re- gistry, 2000–2010. Bone Marrow Transplant. 2016;51(4):536-541.
14. Qari MH, Wali Y, Albagshi MH, et al. Regional consensus opinion for the man- agement of beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis. 2013;8:143.
15. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplan- tation in thalassemia major and sickle cell disease: indications and management rec- ommendations from an international expert panel. Haematologica. 2014;99(5): 811-820.
16. Negre O, Eggimann AV, Beuzard Y, et al. Gene therapy of the b-hemoglobinopathies by lentiviral transfer of the b(A(T87Q))-glo- bin gene. Hum Gene Ther. 2016;27(2):148- 165.
17. Saliba AN, Taher AT. Morbidities in non- transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):82-94.
18. Taher A, Vichinsky E, Musallam K, Cap- pellini MD, Viprakasit V. Blood transfusion. In: Weatherall D, ed. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Fe- deration; 2013.
19. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479- 3488.
20. Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870-882.
21. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in b-thalassemia. Nat Med. 2014;20(4):398-407.
22. Ruckle J, Jacobs M, Kramer W, et al. Single- dose, randomized, double-blind, placebo- controlled study of ACE-011 (ActRIIA- IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744-752.
23. Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haema- tol. 2018;5(2):e63-e72.
24. Porter J, Garbowski M. Novel erythro- poiesis stimulating agents in thalassemia. European Hematology Association Educa- tion Programme. 2015;9:311-320.
25. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia inter- media management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
26. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-b superfam- ily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.
27. Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplas- tic syndromes (PACE-MDS): a multicentre, open-label, phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338-1347.
28. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volun- teers. Am J Hematol. 2014;89(7):766-770.
484
haematologica | 2019; 104(3)